These observations, together with the fact that MECP2 E1 mutations have been found in RTT patients while MECP2 E2 mutations have not been seen in the clinic (18–20) provide further evidence that MEPC2 E1 loss-of-function is the main driver of the RTT phenotype. This evidence concerns the gene MECP2 and Rett syndrome.